These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

451 related items for PubMed ID: 22703861

  • 1. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus.
    Patil HR, Al Badarin FJ, Al Shami HA, Bhatti SK, Lavie CJ, Bell DS, O'Keefe JH.
    Am J Cardiol; 2012 Sep 15; 110(6):826-33. PubMed ID: 22703861
    [Abstract] [Full Text] [Related]

  • 2. Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis.
    Savarese G, D'Amore C, Federici M, De Martino F, Dellegrottaglie S, Marciano C, Ferrazzano F, Losco T, Lund LH, Trimarco B, Rosano GM, Perrone-Filardi P.
    Int J Cardiol; 2016 Oct 01; 220():595-601. PubMed ID: 27390996
    [Abstract] [Full Text] [Related]

  • 3. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.
    White WB, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Fleck P, Heller S, Mehta C, Nissen SE, Perez A, Wilson C, Zannad F.
    Am Heart J; 2011 Oct 01; 162(4):620-626.e1. PubMed ID: 21982652
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cardiovascular outcome trials of glucose-lowering medications: an update.
    Home P.
    Diabetologia; 2019 Mar 01; 62(3):357-369. PubMed ID: 30607467
    [Abstract] [Full Text] [Related]

  • 6. Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus.
    White WB, Pratley R, Fleck P, Munsaka M, Hisada M, Wilson C, Menon V.
    Diabetes Obes Metab; 2013 Jul 01; 15(7):668-73. PubMed ID: 23489301
    [Abstract] [Full Text] [Related]

  • 7. Cardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials.
    Elgendy IY, Mahmoud AN, Barakat AF, Elgendy AY, Saad M, Abuzaid A, Wayangankar SA, Bavry AA.
    Am J Cardiovasc Drugs; 2017 Apr 01; 17(2):143-155. PubMed ID: 27873238
    [Abstract] [Full Text] [Related]

  • 8. The efficacy and safety of dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus patients with severe renal impairment: a meta-analysis.
    Chen M, Liu Y, Jin J, He Q.
    Ren Fail; 2016 Apr 01; 38(4):581-7. PubMed ID: 26915531
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants.
    Wu S, Hopper I, Skiba M, Krum H.
    Cardiovasc Ther; 2014 Aug 01; 32(4):147-58. PubMed ID: 24750644
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety.
    Green JB.
    Postgrad Med; 2012 Jul 01; 124(4):54-61. PubMed ID: 22913894
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [DPP4 inhibitors: what is the cardiovascular risk?].
    Langrand C, Moulin P.
    Rev Prat; 2015 Oct 01; 65(8):1039-41. PubMed ID: 26749701
    [No Abstract] [Full Text] [Related]

  • 19. Oral hypoglycemic agents and the heart failure conundrum: Lessons from and for outcome trials.
    Kappel BA, Marx N, Federici M.
    Nutr Metab Cardiovasc Dis; 2015 Aug 01; 25(8):697-705. PubMed ID: 26164634
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review.
    Frandsen CS, Madsbad S.
    Diabet Med; 2014 Nov 01; 31(11):1293-300. PubMed ID: 25112609
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.